×

Neville Registrars is delighted to welcome iWater Group Limited as the newest addition to its list of client companies.

iWater Group Limited is a water disinfection and decontamination solutions company engaged in the development and delivery of effective, environmentally friendly products for a diverse range of industry sectors, ranging from oil and gas, drinking water, shipping and manufacturing, to farming and livestock.

Further information can be found on the Company's website: https://www.iwatergroup.com

Close

×

RNS Number : 9473I

Osirium Technologies PLC

14 August 2019

 

 

 

 

14 August 2019

 

 

Osirium Technologies plc

 

("Osirium" or "Group")

 

First contract win for Opus

 

 

Osirium (AIM: OSI), a leading vendor of cloud-based cybersecurity software, is pleased to announce the first customer for its new innovative privileged robotic process automation solution, Opus, which was launched in May of this year.

The contract is with a leading asset manager who recently renewed Osirium's full PxM platform for a further three-year term, as announced in May. The customer selected Opus to reduce manual processes, speed up internal customer service and improve consistency of service. Up until now, IT administration operations, such as creating or updating user and system accounts, are repeated many times per day, taking up to an hour each to complete and needing senior staff involvement. End-users become frustrated because of delays in provisioning or updating accounts, with execution of changes proving inconsistent, and the IT organisation wanting to free up resource to deliver business changes faster.

Opus will augment the client's existing ServiceNow infrastructure to automate these tasks. Now, less-experienced IT engineers can perform software updates securely and reliably, with tasks being completed accurately and efficiently in just a few minutes. This will result in improved customer satisfaction, consistency and reporting, and capacity in the team will be freed up to allow more experienced staff to focus on delivering higher-value business initiatives.

David Guyatt, Chief Executive Officer, commented: "Osirium's privileged account security strategy has been significantly strengthened with the launch of two more privileged security products, Opus and PEM which, together with Osirium's PxM platform, maximise our ability to combat privileged security threats, wherever the security concerns may be. This contract is an excellent example of how we can broaden our relationship with existing customers as they appreciate the quality of our products, their ease of implementation and the benefits that they can deliver. Opus has wide applicability and is generating interest across DevOps, NetOps and outside IT in business teams."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

 

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by David Guyatt, CEO.

 

– Ends –

 

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah / Alex Price
Alma PR (Financial PR)	Tel: +44 (0) 20 405 0210
Hilary Buchanan / Josh Royston / Kieran Breheny

 

Notes to Editors:

 

About Osirium

Osirium Technologies plc (AIM: OSI) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Management ("PAM") software. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen. 

 

Osirium has defined and delivered what the Directors view as the next generation PAM solution.  The team has developed the concept of a Virtual Air Gap to separate users from passwords.  Built on Robotic Automation technology, Osirium's Privileged Task Management module further strengthens Privileged Account security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers.   Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched "Opus", providing a highly-flexible platform for automating essential IT processes to set a new benchmark in Privileged IT Process Automation.

 

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016.  For further information please visit www.osirium.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTZMGMRGFLGLZZ

Close

×

RNS Number : 6231I

DeepMatter Group PLC

12 August 2019

 

 

Launch of DigitalGlassware™ Online Portal

First look at the uniquely rich, contextualised experiment data recorded by DigitalGlassware™, aiming to solve the reproducibility problem in chemistry

 

12 August 2019 – DeepMatter, the AIM-listed company at the forefront of digitizing chemistry, today announces the launch of its open access DigitalGlasswareTM online portal, which allows the scientific world to view and interact with the shareable data originated from chemistry lab experiments conducted using DeepMatter's proprietary technology.

 

The online portal allows individuals to visualise and interact with the uniquely contextualised, rich and real-time data that DeepMatter's innovative cloud-based platform (DigitalGlassware™) generates recording experiments. This includes data points such as temperature, UV light levels, pressure and more.

 

To demonstrate the capabilities of the technology, the DigitalGlasswareTM online platform has today been populated with the data from an example experiment: a selective amination of an alcohol under mild conditions.

 

Going forward, the portal will be regularly updated with the outcomes of other experiments, showing how DigitalGlassware™ works under real reaction scenarios and, crucially, how it can save time and money and increase lab productivity. These will be supported by blog post 'data stories', providing guidance to help users familiarise themselves with DigitalGlassware™.

 

The online portal can be found at https://public.deepmatter.tech;

and the associated blog post at: https://www.deepmatter.io/blog

 

This one example is a demonstration of the depth of data that will ultimately be openly accessible across an increasing library of experiments through the DigitalGlasswareTM digital platform.

 

This level of data sharing will allow scientists to re-create experiments to a greater degree of accuracy. Ultimately, the aim is to solve the billion-dollar reproducibility problem.

 

The portal will be consistently developed and refined, with chemists eventually able to upload their own 'recipes' and run data through the portal.

 

Mark Warne, CEO of DeepMatter, commented:

 

"This is a fantastic opportunity to demonstrate our DigitalGlassware™ platform to a broader audience of chemists. Our aim is for our software to become truly integral to research and process chemistry, providing those involved with a cost-effective, easy-to-use solution that will save significant time, effort and money. The launch of this platform is a significant step towards achieving the sharing and recording of detailed data in real time across the chemistry industry, making reproducibility much more achievable."

 

About DeepMatter

 

DeepMatter Group Plc is a big data and analysis company which has built a technology platform – DigitalGlassware™, focused on enabling reproducibility in chemistry. It continues to develop this software to deliver applications resulting in new optimised chemicals, materials and formulations in such commercially significant areas as pharmaceutical research, fine chemicals, scientific publications and teaching. DeepMatter is at the forefront of the digitization of chemistry, which will ultimately see the enabling of an autonomous synthesis engine, the Chemputer™.

 

Paying clients of the DigitalGlasswareTM platform are able to nominate which data remains proprietary, for their sole use, and which can be made shareable via the Online Portal.

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAPLMATMBJMBRL

Close

×

RNS Number : 2639I

Avanti Communications Group Plc

07 August 2019

 

7 August 2019

Avanti Communications Group plc
 

Successful Launch of HYLAS 3

 

Avanti Communications Group PLC (AIM: AVN) ("Avanti" or the "Company"), a leading provider of satellite data communications services in Europe, the Middle East and Africa, announces the successful launch of HYLAS 3 from Kourou, French Guiana on Ariane Flight VA249 on Tuesday 6 August 2019.

The Ariane 5 rocket launched HYLAS 3 into its correct orbit on schedule. HYLAS 3 successfully separated from the Ariane 5 rocket on time and telemetry was received by the control centre at the European Spaceport. 

HYLAS 3 is a hosted Ka-band communications payload on board the EDRS-C satellite – a public private partnership between the European Space Agency and Airbus.  This is the second successful launch of an Avanti payload in as many years and brings total fleet capacity over EMEA to 50 GHz.

Kyle Whitehill, Chief Executive of Avanti, said:

"I'm pleased to announce HYLAS 3 has been successfully launched thereby completing our capital expenditure cycle. The satellite will undertake a series of pre-planned in-orbit acceptance tests over the coming months before we commence service for customers."

 

For further information, please contact:

Avanti Communications	Nigel Fox Tel: +44 (0)20 7749 1600
Cenkos Securities (Nomad)	Max Hartley, Katy Birkin Tel: +44 (0)20 7397 8900
Newgate Communications	Adam Lloyd Tel: +44 (0)20 3757 9842

 

About Avanti

Avanti connects people wherever they are. Through the HYLAS satellite fleet and partners in 118 countries, our network provides ubiquitous internet service to an end market of over 1.7bn people. Avanti works together with like-minded people and organisations to go the extra mile, developing new, innovative and pioneering satellite solutions that help to liberate the potential of people, businesses and government departments across EMEA. We have invested $1.2bn in the latest Ka-band satellite technology and shaped it to meet our customers' aspirations.

Avanti is listed in London on AIM (AVN: LSE). www.avantiplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCBGGDIXDGBGCR

Close

×

RNS Number : 8189H

Dev Clever Holdings PLC

05 August 2019

 

Dev Clever Holdings plc

("Dev Clever" or "the Company") 

Vanguard: Fight for Rudiarius VR New Leisure Partner 

 

Dev Clever, a leading developer of mobile and immersive consumer experiences, is pleased to announce that its competitive multi-player, virtual reality game "Vanguard: Fight for Rudiarius" has been successfully installed in its first Teamsport indoor go-karting venue, in Birmingham UK.

 

Teamsport is the number one indoor go-karting operator in the UK, with thirty four indoor go-karting venues across the country.  The "Pay Per Play" competitive VR experience Vanguard: Fight for Rudiarius has been installed in Birmingham on a 10-week trial with a view to then rolling out the multiplayer VR experience to other Teamsport locations across the UK.    

 

The out of home, multi-player game allows players to compete against each other as space-age gladiators in full 360' virtual reality. The "Pay Per Play" game version of "Vanguard: Fight for Rudiarius" has been created specifically for installation in venues across the UK leisure and hospitality sector and has been developed using Dev Clever's proprietary immersive framework that enables rapid development of immersive, multiplayer games and experiences.  

 

Further releases of the Vanguard game are to include  "Pay to Download" and "In App. Purchase" versions which are downloadable for mobile users via the Apple App Store and Google Play Store, for VR users via the Oculus Store and PC users on windows, leading to full cross-platform integration to include users on PlayStation, Xbox and Nintendo Switch. 

 

 

Chris Jeffries CEO Dev Clever said:

 

Teamsport is an exciting new leisure partner for Dev Clever.  As the number one indoor go-karting operator in the UK they provide thousands of customers each month with a competitive motor sports experience. The out of home Vanguard game offers an extension to the customers experience and allows them to carry on the battle from the race track and compete as a group in competitive VR. I see this as an ideal consumer audience for Vanguard and I'm delighted to be working with the market leaders in this sector.   

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAEZLFBKVFXBBD

Close

×

Neville Registrars is delighted to welcome Elecosoft plc as the newest addition to its list of client companies.

Elecosoft provides integrated software and associated services to the worldwide architectural, engineering, construction and owner/operator (AECO) industries.

Further information can be found on the Company's website: https://www.elecosoft.com/

Close

×

RNS Number : 0503G

Midatech Pharma PLC

19 July 2019

 

 

19 July 2019

Midatech Pharma PLC

 

("Midatech" or the "Company")

 

 

Midatech Announces Safety Results from First in Human Study for Injectable MidaCore® Gold Nano Particle Diabetes Vaccine Programme – MTX102

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce positive results from a first in human study of its MTX102 immuno-tolerising vaccine product candidate in diabetes.

 

The focus of this Phase I study is to assess the safety of MTX102.  Five recently diagnosed Type I diabetes patients, all meeting strict genetic parameters, were recruited onto the study and received the study drug.  MTX102 was well tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported. 

 

This is an important study of systemic injectable administration of Midatech's gold nanoparticle technology, MidaCore®.  It provides promising safety validation of the MidaCore® technology as a platform for the development of medications for use in humans.

 

Colin Dayan, Principal Investigator, said "This EU project brings together a consortium comprising eight complementary partners, including two small and medium enterprises, one technology transfer company and five academic laboratories, from four EU states (UK, France, the Netherlands and Sweden) and Israel.  We are pleased to have completed the initial project, based on Midatech's gold nanoparticle technology, to evaluate a vaccine approach for the treatment of Type 1 diabetes.  The study now enters a follow up stage, at the end of which we will review the data and programme, together with the EU consortium partners.

 

Craig Cook, CEO of Midatech Pharma PLC, commented: "This EU funded programme is an invaluable project to further develop, understand and evaluate Midatech's gold nanoparticle technology, MidaCore®.  This is the first human study to assess the safety of MidaCore® when injected into patients, and we are pleased that the data generated to date validates the technology as a potentially innovative treatment platform for medical applications."

 

The aim of the study to assess safety has been achieved and no further patients will be recruited.  All patients on the trial will now enter the follow up phase which will conclude around Q1 2020.

 

MTX102 is based on Midatech's MidaCore® technology platform of ultra-small gold nanoparticle drug conjugates.  MidaCore® is being developed as an immunotherapeutic as well as a chemotherapeutic platform.  In vaccines it represents an innovative approach that takes advantage of the multifunctional properties of gold nanoparticles to combine immunogenic peptides and tolerising agents and deliver them more efficiently to immune cells to dampen down autoimmune responses in diseases such as diabetes.

 

Midatech is part of a consortium of academic institutions and industry partners investigating the potential of MTX102 as a vaccine to prevent or limit the damage that occurs when the body attacks its own insulin producing cells in the pancreas.  This project is funded by the European Union up to the completion of Phase I study.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

For more information, please contact:

 

Midatech Pharma PLC

Dr Craig Cook, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance) 

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring / Heather Armstrong

Tel: +44 (0)20 3934 6630

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

About Midatech Pharma PLC

 

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body.  The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

 

The Company has developed three in house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 

·    Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

·    MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

·    MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

 

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D makes medicine better, lowers technical risks, accelerates regulatory approval and route to market, and provides newly patentable products.  The platform nature of the technologies allows the potential for multiple drug assets rather than being reliant on a single or limited programmes.

 

Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain.  For more information please visit www.midatechpharma.com

 

Forward-Looking Statements

 

Certain statements in this announcement may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements expressed or implied regarding our plans, goals, and milestones, our ability to successfully test, manufacture, produce or commercialise products for conditions using our drug delivery platforms, the ability for products in development, including MTX102, to achieve positive clinical results, the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions and the associated costs of such studies, trials or submissions, and other economic, business and/or competitive factors. The risks included are not exhaustive. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that we shall file from time to time or announcements that may be made by the Company in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning the Company are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, we do not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCUWAARKNABAUR

Close

×

RNS Number : 8248F

Cadence Minerals PLC

17 July 2019

 

Cadence Minerals Plc

 

("Cadence Minerals", "Cadence" or "the Company")

 

Hastings Technology Metals (ASX:HAS) Confirms No Appeals on EPA Recommendation of Environmental Approval for Proposal to Mine & Process Rare Earths at Yangibana.

 

Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) is pleased to announce Hastings Technology Metals (ASX:HAS) ("Hastings"), Cadence's joint venture partner at the Yangibana Rare Earth Project in the Gascoyne region of Western Australia ("Yangibana Project"), has announced that the Appeals Registrar (WA Office of the Appeals Convenor) has not received any appeals on the EPA Assessment Report, which recommends approval of the Yangibana Project subject to the proposed conditions.

Cadence owns 30% of the Yangibana North., Gossan, Hook, Kanes Gossan, Lions Ear and Bald Hill North Rare Earth Deposit which form part of the Yangibana Rare Earth Deposit. Probable Ore Reserves of some 2.1 million tonnes at 1.66% total rare earth elements are contained within 30% owned joint venture tenements. Further details of these reserves and pre-feasibility study can be found at: http://irservices.netbuilder.com/ir/cadence/newsArticle.php?ST=REM&id=2688632.

Highlights:

·      The Appeals Registrar (WA Office of the Appeals Convenor) has notified Hastings that they have received no appeals on the EPA's recommendation to approve the Yangibana Project.

·      Next step in the approvals process is consultation with the Decision Making Authorities ("DMAs"), i.e. Ministers for Water, Mines and Aboriginal Affairs to obtain their agreement to the implementation of the project in accordance with the proposed conditions.

The DMAs will be provided with the draft conditions (as detailed in the EPA Assessment Report) for their consideration and must then provide their agreement to the implementation of the proposal subject to the draft conditions. The Minister for Environment will then consider the proposal and EPA recommendation.

The Yangibana project includes the development of five open pit mines, groundwater abstraction, on-site processing of ore, tailings storage facilities, access and haul roads and supporting infrastructure such as accommodation facilities, administration buildings and an airstrip.

The full release can be found at: https://www.asx.com.au/asxpdf/20190717/pdf/446p7m8wcdgm40.pdf

– Ends –

 

For further information:

Cadence Minerals plc	+44 (0) 207 440 0647
Andrew Suckling
Kiran Morzaria
WH Ireland Limited (NOMAD & Broker)	+44 (0) 207 220 1666
James Joyce
James Sinclair-Ford
Novum Securities Limited (Joint Broker)	+44 (0) 207 399 9400
Jon Belliss

 

Qualified Person

Kiran Morzaria B.Eng. (ACSM), MBA, has reviewed and approved the information contained in this announcement. Kiran holds a Bachelor of Engineering (Industrial Geology) from the Camborne School of Mines and an MBA (Finance) from CASS Business School.

 

Forward-Looking Statements:

Certain statements in this announcement are or may be deemed to be forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ''believe'' ''could'' "should" ''envisage'' ''estimate'' ''intend'' ''may'' ''plan'' ''will'' or the negative of those variations or comparable expressions including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth results of operations performance future capital and other expenditures (including the amount. nature and sources of funding thereof) competitive advantages business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.  Many factors could cause actual results to differ materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions competition environmental and other regulatory changes actions by governmental authorities the availability of capital markets reliance on key personnel uninsured and underinsured losses and other factors many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions. The Company cannot assure investors that actual results will be consistent with such forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDGGUQCMUPBURM

Close

×

Neville Registrars is pleased to announce that it will be exhibiting at The ICSA Annual Conference 2019 to be held on the 9th & 10th July (8.30am – 5.30pm) at the ExceL Conference Centre, London.

Please find us at Stand 31 where we will be delighted to discuss your Company's requirements and outline the numerous services/products we can offer.

Close

×

RNS Number : 4280E

ValiRx PLC

04 July 2019

 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

UPDATE RE VAL301

FOR THE TREATMENT OF ENDOMETRIOSIS

 

"ValiRx progresses VAL301 Clinical Development Plan"

 

London, UK., 04 July 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company's clinical team has signed an agreement to work with Aptus Clinical Ltd ("Aptus"), the UK based, clinical Contract Research Organisation ("CRO"), to effectuate a clinical development plan for VAL301 incorporating a Phase I/II study design concept in Endometriosis.

 

Aptus will be working with ValiRx on regulatory, technical and scientific areas, in order to bring VAL301 nearer to the clinic.

 

Endometriosis is a benign, oestrogen -dependent chronic condition, characterised by endometrial tissue growth outside of the uterus.  Symptoms including heavy painful periods, pain with intercourse and infertility are often severe and are associated with a decreased quality of life for young women. The condition affects an estimated 1 in 10 women during their reproductive years, equating to approximately 176 million women worldwide*, posing a high economic burden.

 

VAL301 is derived from the same active pharmaceutical ingredient as VAL201, which is currently in a Phase I/II clinical trial where the compound has demonstrated safety and has been well tolerated. These positive results will be used to strengthen the clinical application of the development programme.  Pre-clinical studies indicate that treatment with VAL301 should not affect bone density or fertility, two of the major problems associated with current medical treatments for endometriosis. ValiRx intends to develop VAL301 as a non-invasive, effective and better tolerated treatment for this debilitating condition.

*Source: https://www.ncbi.nlm.nih.gov/pubmed/30026507

 

Dr Satu Vainikka, CEO of ValiRx, commented: "Our agreement with Aptus represents an important stage in preparing the VAL301 compound for clinical study. I look forward to VAL301's future development and its potential to benefit women who suffer from this extremely painful condition".

 

Dr Steve McConchie, Co-founder & CEO of Aptus, added: "We are delighted to have been selected by ValiRx to work on the development plan options for VAL301 in endometriosis. We look forward to exploring some innovative opportunities with the team in order to optimise the programme delivery timelines and progress this important potential treatment rapidly to patients".

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Novum Securities Limited Colin Rowbury	Tel: +44 (0) 20 7399 9400

 

Notes for Editors

 

About Aptus

Aptus is a UK based, clinical CRO with particular expertise in oncology, rare diseases and advanced (cell and gene) therapies. The company provides design, set-up, management and monitoring of early phase clinical trials. In addition, it supports clients with a range of specialist services that include quality management frameworks, clinical governance support and a number of digital solutions that facilitate data storage, analysis and visualisations.

 

Aptus are partners in iMATCH (innovate Manchester Advanced Therapy Centre Hub), a consortium of experts from industry, academia and the NHS, funded by Innovate UK. The iMATCH objective is to accelerate the safe and effective delivery of advanced therapies to increasing numbers of patients within the NHS.  Aptus are also preferred suppliers to the Cell and Gene Therapy Catapult.

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCBRGDRXSGBGCX

Close